21. Oktober 2021 – In a press release dated 12 October 2021, Tübingen-based biopharma company CureVac announced that it would no longer be developing its first-generation COVID-19 vaccine to market readiness, and would instead be focusing on a second-generation COVID-19 vaccine.

Thus, on 18 October 2021 CureVac Swiss AG also withdrew the application for authorisation that it had submitted to Swissmedic, the Swiss Agency for Therapeutic Products, in April 2021.

For more information see here.